OtherTheranostics
Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer
John Violet, Shahneen Sandhu, Amir Iravani, Justin Ferdinandus, Sue Ping Thang, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, David A. Pattison, Alexis Beaulieu, Jennifer Mooi, Christina Guo, Victor Kalff, Declan G Murphy, Price Jackson, Peter Eu, Mark Scalzo, Scott Williams, Rod J Hicks and Michael S Hofman
Journal of Nuclear Medicine November 2019, jnumed.119.236414; DOI: https://doi.org/10.2967/jnumed.119.236414
John Violet
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Shahneen Sandhu
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Amir Iravani
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Justin Ferdinandus
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Sue Ping Thang
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Grace Kong
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Aravind Ravi Kumar
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Tim Akhurst
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
David A. Pattison
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Alexis Beaulieu
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Jennifer Mooi
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Christina Guo
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Victor Kalff
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Declan G Murphy
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Price Jackson
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Peter Eu
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Mark Scalzo
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Scott Williams
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Rod J Hicks
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Michael S Hofman
Peter MacCallum Cancer Centre, Melbourne VIC, Australia, AUSTRALIA
Article Figures & Data
Additional Files
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer
John Violet, Shahneen Sandhu, Amir Iravani, Justin Ferdinandus, Sue Ping Thang, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, David A. Pattison, Alexis Beaulieu, Jennifer Mooi, Christina Guo, Victor Kalff, Declan G Murphy, Price Jackson, Peter Eu, Mark Scalzo, Scott Williams, Rod J Hicks, Michael S Hofman
Journal of Nuclear Medicine Nov 2019, jnumed.119.236414; DOI: 10.2967/jnumed.119.236414
Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer
John Violet, Shahneen Sandhu, Amir Iravani, Justin Ferdinandus, Sue Ping Thang, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, David A. Pattison, Alexis Beaulieu, Jennifer Mooi, Christina Guo, Victor Kalff, Declan G Murphy, Price Jackson, Peter Eu, Mark Scalzo, Scott Williams, Rod J Hicks, Michael S Hofman
Journal of Nuclear Medicine Nov 2019, jnumed.119.236414; DOI: 10.2967/jnumed.119.236414
Jump to section
Related Articles
Cited By...
- Is 161Tb Really Happening?
- Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [177Lu]Lu-PSMA-617 Therapy
- Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers
- Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy
- Unraveling the Impact of 177Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation
- Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of 177Lu-PSMA I&T
- Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy
- SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
- SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
- Clinical Translation of Targeted {alpha}-Therapy: An Evolution or a Revolution?
- Clinical Translation of Targeted {alpha}-Therapy: An Evolution or a Revolution?
- 177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy
- Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)
- 177Lu-PSMA Therapy
- Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
- Effects of 225Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis
- A Comparison of 18F-DCFPyL, 18F-NaF, and 18F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer
- The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation
- Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?
- Bringing VISION to Nuclear Medicine: Accelerating Evidence and Changing Paradigms with Theranostics
- Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
- Radionuclide Therapy in Prostate Cancer: From Standalone to Combination PSMA Theranostics
- Assessing Response to 177Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria
- Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice
- Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
- RESIST-PC: U.S. Academic Foray into PSMA Theranostic Trials
- Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
- Perspectives on Cutting-Edge Clinical Trials: A Conversation Between Michael Hofman, Johannes Czernin, and Jeremie Calais
- 177Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine
- The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
- John Violet: radiation oncologist and physician scientist who pioneered targeted radionuclide therapy for prostate cancer
- Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer